

Pharmacy Formulary Updates for November 2020

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in November 2020:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
Zepzelca (lurbinectedin)	MB
Barhemsys (amisulpride)	MB
Fensolvi (leuprolide)	MB
Fintepla (fenfluramine)	T3; PA
Rukobia (fostemsavir)	T2
Harvoni (ledipasvir/sofosbuvir)	T2; PA; SP; QL (30/30)
Sovaldi (sofosbuvir)	NC; SP; QL (30/30)
zilxi (minocycline hcl micronized)	NC
Xcopri	T2
Lo Loestrin Fe	T2 (\$0 cost share, ACA)
Natazia	T2 (\$0 cost share, ACA)
Taytulla	T2 (\$0 cost share, ACA)
neonatal/DHA	NC
Uplizna (inebilizumab-cdon)	MB; PA
dimethyl fumarate starter pack	NC; SP; QL (1 fill per lifetime)
Vumerity	T2; SP
Zeposia	T2; SP
Bafiertam	T2; SP
ciprofloxacin-dexamethasone	T2
deferasirox	T2
ketorolac tromethamine	NC
pantoprazole sodium for delayed release	T2; PA; QL (PA applies to those 12 and older)
metyrosine	T2
tolvaptan	T2; QL (14 tabs/7 days)
emtracitabine	T2

Jynarque	T3; PA
Semglee	NC
Promacta 25 mg	T2; PA; SP; QL
Promacta 12.5 mg	T2; PA; SP; QL
tobramycin	T2
efavirenz-lamivudine-tenofovir	T2
Peg 3350-KCl-NaCl-Na sulfate-Na ascorbate-C	T2; ACA Bowel Prep \$0 for members age 50-74
Dojolvi	T2; PA
Inqovi	T2; SP; PA

Key:

MB: Medical Benefit **QL:** Quantity Limitation
NC: Not covered **SP:** Specialty Pharmacy - provided
NTM: New-to-market through CVS/specialty
PA: Prior Authorization **ST:** Step Therapy